CA3206612A1 - Topical ophthalmological compositions - Google Patents
Topical ophthalmological compositions Download PDFInfo
- Publication number
- CA3206612A1 CA3206612A1 CA3206612A CA3206612A CA3206612A1 CA 3206612 A1 CA3206612 A1 CA 3206612A1 CA 3206612 A CA3206612 A CA 3206612A CA 3206612 A CA3206612 A CA 3206612A CA 3206612 A1 CA3206612 A1 CA 3206612A1
- Authority
- CA
- Canada
- Prior art keywords
- topical ophthalmological
- ophthalmological composition
- atropine
- topical
- mct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163145091P | 2021-02-03 | 2021-02-03 | |
| US63/145,091 | 2021-02-03 | ||
| PCT/US2022/014811 WO2022169788A1 (en) | 2021-02-03 | 2022-02-02 | Topical ophthalmological compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3206612A1 true CA3206612A1 (en) | 2022-08-11 |
Family
ID=82741579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3206612A Pending CA3206612A1 (en) | 2021-02-03 | 2022-02-02 | Topical ophthalmological compositions |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12070501B1 (https=) |
| EP (1) | EP4288151A4 (https=) |
| JP (2) | JP7749020B2 (https=) |
| KR (1) | KR20230142548A (https=) |
| AU (1) | AU2022217160A1 (https=) |
| CA (1) | CA3206612A1 (https=) |
| MX (1) | MX2023009091A (https=) |
| WO (1) | WO2022169788A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL268457B (en) * | 2019-08-04 | 2022-05-01 | Omega 3 Galilee Ltd | Oil- suspension of edible solids and methods of preparing the same |
| US11191751B1 (en) * | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
| CN119789854A (zh) * | 2023-08-04 | 2025-04-08 | Ads医疗有限责任公司 | 用于递送眼科活性物的组合物和方法 |
| WO2025131038A1 (en) * | 2023-12-21 | 2025-06-26 | Ads Therapeutics Llc | Compositions and methods for delivery of pharmaceutical actives |
| WO2025259674A1 (en) * | 2024-06-11 | 2025-12-18 | Ads Therapeutics Llc | Compositions and methods for delivery of pharmaceutical actives |
| WO2026003129A1 (en) * | 2024-06-26 | 2026-01-02 | Novaliq Gmbh | Stabilization of (r)-ruxolitinib |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| DE10030378A1 (de) | 2000-06-21 | 2002-03-14 | Audit Inst For Medical Service | Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen |
| CN101049287A (zh) | 2006-04-07 | 2007-10-10 | 财团法人长庚纪念医院 | 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法 |
| US20070254914A1 (en) | 2006-05-01 | 2007-11-01 | Non-Profit Organization Chang Gung Memorial Hospital | Low-concentration atropine solution for preventing myopia progression and preparing method thereof |
| US20100323978A1 (en) * | 2009-06-22 | 2010-12-23 | Calvin Hanna | Non-aqueous oil delivery system for ophthalmic drugs |
| PL2547323T3 (pl) | 2010-03-17 | 2016-07-29 | Novaliq Gmbh | Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| WO2012161655A1 (en) | 2011-05-23 | 2012-11-29 | Singapore Health Services Pte Ltd | Composition and/or method for reducing and/or preventing myopia progression comprising atropine |
| CN102526051A (zh) * | 2012-03-09 | 2012-07-04 | 哈尔滨医科大学 | 一种治疗真菌性角膜炎的眼药膏 |
| CN113679699B (zh) * | 2012-09-12 | 2022-10-28 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| AU2013314303B2 (en) | 2012-09-12 | 2018-01-18 | Novaliq Gmbh | Semifluorinated alkane compositions |
| EP2783703A1 (en) | 2013-03-25 | 2014-10-01 | B. Braun Melsungen AG | Semifluorocarbon compound containing contrast agent |
| WO2016172712A2 (en) * | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| CA2976952A1 (en) | 2015-03-05 | 2016-09-09 | Allergan, Inc. | Self-emulsifying drug delivery system (sedds) for ophthalmic drug delivery |
| AU2017333420A1 (en) | 2016-09-28 | 2019-04-04 | Novaliq Gmbh | Compositions comprising a cannabinoid receptor binding ligand |
| US11510931B2 (en) | 2016-09-28 | 2022-11-29 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
| BR112019012568A2 (pt) | 2016-12-22 | 2019-11-26 | Novaliq Gmbh | composições compreendendo tacrolimus para o tratamento de doenças intraoculares inflamatórias |
| PH12019501945B1 (en) | 2017-02-21 | 2024-02-21 | Singapore Health Serv Pte Ltd | Composition and method for preventing or delaying onset of myopia comprising atropine |
| WO2018228975A1 (en) | 2017-06-12 | 2018-12-20 | Novaliq Gmbh | Process for the preparation of semifluorinated alkanes using grignard reagents |
| MX2020003534A (es) | 2017-09-27 | 2020-07-29 | Novaliq Gmbh | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. |
| WO2019068763A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
| SG11202102820VA (en) | 2018-10-12 | 2021-04-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| WO2020152046A1 (en) | 2019-01-21 | 2020-07-30 | Novaliq Gmbh | Pharmaceutical composition for the treatment of ocular neovascularisation |
| CA3128224A1 (en) * | 2019-02-01 | 2020-08-06 | Aerie Pharmaceuticals, Inc. | Compounds, compositions and methods for treatment of myopia |
| US11191751B1 (en) | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
-
2022
- 2022-02-02 MX MX2023009091A patent/MX2023009091A/es unknown
- 2022-02-02 KR KR1020237029544A patent/KR20230142548A/ko active Pending
- 2022-02-02 WO PCT/US2022/014811 patent/WO2022169788A1/en not_active Ceased
- 2022-02-02 EP EP22750270.5A patent/EP4288151A4/en active Pending
- 2022-02-02 AU AU2022217160A patent/AU2022217160A1/en active Pending
- 2022-02-02 CA CA3206612A patent/CA3206612A1/en active Pending
- 2022-02-02 JP JP2023547047A patent/JP7749020B2/ja active Active
- 2022-10-28 US US17/976,660 patent/US12070501B1/en active Active
-
2024
- 2024-07-10 US US18/768,656 patent/US12485177B2/en active Active
-
2025
- 2025-09-22 JP JP2025157079A patent/JP2025176201A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022217160A9 (en) | 2025-01-30 |
| JP2024511695A (ja) | 2024-03-15 |
| WO2022169788A1 (en) | 2022-08-11 |
| JP7749020B2 (ja) | 2025-10-03 |
| KR20230142548A (ko) | 2023-10-11 |
| MX2023009091A (es) | 2023-08-09 |
| JP2025176201A (ja) | 2025-12-03 |
| US20250000980A1 (en) | 2025-01-02 |
| US12070501B1 (en) | 2024-08-27 |
| EP4288151A1 (en) | 2023-12-13 |
| US12485177B2 (en) | 2025-12-02 |
| EP4288151A4 (en) | 2025-01-01 |
| AU2022217160A1 (en) | 2023-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12485177B2 (en) | Topical ophthalmological compositions | |
| EP4225284B1 (en) | Topical ophthalmological compositions | |
| US11058684B2 (en) | Method of increasing bioavailability and/or prolonging ophthalmic action of a drug | |
| JP7353292B2 (ja) | ネビボロールを含む医薬組成物 | |
| CA2780453A1 (en) | Treating xerophthalmia with compounds increasing meibomian gland secretion | |
| WO2016014437A1 (en) | Ophthalmic compositions of rifamycins and uses thereof | |
| US20260124305A1 (en) | Topical ophthalmological compositions | |
| Vale et al. | Drugs and the Eye: Sponsored by the British Optical Association | |
| US6534541B1 (en) | Treatment of ocular disorders | |
| CN120093684A (zh) | 局部眼科组合物 | |
| EP0205606B1 (en) | Pharmaceutical compositions and their use as mydriatics | |
| HK40086649A (zh) | 局部眼科组合物 | |
| CN120732828A (zh) | 一种含有ar-15512的组合物及其制备方法和应用 | |
| HK40044057A (en) | Pharmaceutical compositions comprising nebivolol | |
| Sahu et al. | In-situ gel ocular drug delivery system for the management of ocular disorders: An overview | |
| JPH06511014A (ja) | 眼への投与に用いる、緩衝剤系を含有するベラパミル塩酸製剤などの眼科用液剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250203 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250203 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - SMALL Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251202 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251202 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260130 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260130 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260130 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260213 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260213 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260213 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260302 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260302 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260302 |